Dow Jones
33.761,05 +424,35 (+1,27%) Nasdaq
13.047,19 +267,29 (+2,09%) Nikkei 225
28.710,38 +163,40 (+0,57%) EUR/USD
1,0267 +0,0009 (+0,09%) BTC-EUR
23.745,96 -256,56 (-1,07%) CMC Crypto 200
582,14 +10,86 (+1,90%)
Certara, Inc. (CERT)
Dopo ore:
| Chiusura precedente | 20,19 |
| Aperto | 16,99 |
| Denaro | 17,00 x 4000 |
| Lettera | 18,68 x 900 |
| Min-Max giorno | 16,73 - 17,70 |
| Intervallo di 52 settimane | 16,17 - 45,48 |
| Volume | |
| Media Volume | 611.616 |
| Capitalizzazione | 2,808B |
| Beta (5 anni mensile) | N/D |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,09 |
| Prossima data utili | 07 nov 2022 - 11 nov 2022 |
| Rendimento e dividendo (forward) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 25,21 |
- GlobeNewswire
Certara Announces Secondary Offering
PRINCETON, N.J., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT) (“Certara”), a global leader in biosimulation, today announced the sale by certain stockholders (the “Selling Stockholders”), including EQT Avatar Parent L.P., in an underwritten secondary offering of 7,000,000 shares of common stock of Certara pursuant to a registration statement filed by Certara with the U.S. Securities and Exchange Commission (the “SEC”). In connection with the offering, the Selling Stockholders h
- GlobeNewswire
Certara Reports Second Quarter 2022 Financial Results
Biosimulation software and services fuel second quarter growthPRINCETON, N.J., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the second quarter of fiscal year 2022 and adjusted its full year guidance. Second Quarter Highlights: Revenue was $82.8 million, compared to $70.1 million in the second quarter of 2021, representing growth of 18% over the second quarter of 2021 on a reported basis and 21% at const
- GlobeNewswire
Certara Introduces Update of Pinnacle 21™ Enterprise and New Pinnacle 21™ Data Exchange Module
New automation, analytics and collaboration features save time and ensure regulatory compliance PRINCETON, N.J., Aug. 05, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the feature release 5.2.0 of Pinnacle 21 Enterprise, the Company’s flagship software for validating clinical trial data for biosimulation and regulatory submissions. It also introduced the new Pinnacle 21 Data Exchange product, an integrated module that streamlines the pro
